Nov 7 Statement | UMR Congratulates Dr. Monica Bertagnolli on her Confirmation as the next NIH Director
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
2023 Rural State Analysis | UMR's Newest Report Reveals the Exponential Impact of NIH Research Funding in Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Wyss Institute to accelerate drug testing for COVID treatment

The Wyss Institute and the U.S. Defense Advanced Research Projects Agency (DARPA) have signed an agreement worth up to $16 million over the next year to use Wyss technologies to identify and test FDA-approved drugs that could be repurposed to prevent or treat COVID-19. Specifically, DARPA will use the computational drug-discovery pipelines and human organ chip technologies developed by the Wyss Institute for Biologically Inspired Engineering at Harvard University. (For more on how organ chip technologies work, listen to UMR’s Amazing Things Podcast episode “a conversation with NCAT’s Dr. Lucie Low” – listen here.)